Angie You - 20 Jun 2025 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Reporting relationship: Director
Issuer ticker: ORIC
Reported as of: 20 Jun 2025
Net transaction value: +$262,899
SEC form: 4
Accepted by SEC: 23 Jun 2025, 20:05:17 UTC
Prior SEC filing: 06 Jan 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Christian Kuhlen, attorney-in-fact

Key filing fact

Angie You filed Form 4 for Oric Pharmaceuticals, Inc. (ORIC) on 23 Jun 2025.

Key facts

This page summarizes Angie You's Form 4 filing for Oric Pharmaceuticals, Inc. (ORIC).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 23 Jun 2025, 20:05.

Change

Previous filing in this sequence was filed on 06 Jan 2025.
Current net transaction value: +$262,899.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001647664 Primary reporting owner

You Angie

Relationship: Director
Address: C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Christian Kuhlen, attorney-in-fact
Signature date: 23 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORIC transaction

Common Stock

Purchase

Transaction value: $249,669
Shares: +26,597
Change %
Price: $9.39
Shares after: 26,597
Date: 20 Jun 2025
Ownership: Direct
Footnotes: F1

ORIC transaction

Common Stock

Purchase

Transaction value: $13,230
Shares: +1,403
Change %: +5.3%
Price: $9.43
Shares after: 28,000
Date: 23 Jun 2025
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the weighted average share price of an aggregate total of 26,597 shares purchased in the price range of $9.14 to $9.50 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.